Synergy Pharmaceuticals to Present at 2012 BIO International Convention
13 Junho 2012 - 10:15AM
Synergy Pharmaceuticals, Inc. (Nasdaq:SGYPD) (Nasdaq:SGYPU)
(Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal
disorders and diseases, today announced that its President and CEO,
Gary S. Jacob, Ph.D, will present at the 2012 Biotechnology
Industry Organization (BIO) Business Forum and International
Convention taking place June 18-21, 2012 at the Boston Convention
& Exhibition Center in Boston, MA.
Dr. Jacob will provide an update on Synergy's lead drug
plecanatide and a corporate overview on Tuesday, June 19, 2012 at
3:45 p.m. ET.
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the
development of new drugs to treat gastrointestinal disorders and
diseases. Synergy's lead proprietary drug candidate plecanatide is
a synthetic analog of the human gastrointestinal hormone
uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. The company completed
a Phase I study of plecanatide in healthy volunteers and a Phase
IIa clinical trial in CIC patients. In October, 2011, Synergy
initiated dosing of patients in a major Phase II/III clinical trial
of plecanatide to treat chronic idiopathic constipation.
Plecanatide is also being developed to treat
constipation-predominant irritable bowel syndrome, with the first
trial in IBS-C patients planned for 2012. Synergy's second GC-C
agonist SP-333 is currently in pre-clinical development to treat
inflammatory bowel diseases. More information is available at
http://www.synergypharma.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "planned," "believe,"
"forecast," "estimated," "expected," and "intend," among others.
These forward-looking statements are based on Synergy's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and
litigation; uncertainties of government or third party payer
reimbursement; limited sales and marketing efforts and dependence
upon third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As
with any pharmaceutical under development, there are significant
risks in the development, regulatory approval and commercialization
of new products. There are no guarantees that future clinical
trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for
any indication or prove to be commercially successful. Synergy does
not undertake any obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in Synergy's Form 10-K for the year ended December 31,
2011 and other periodic reports filed with the Securities and
Exchange Commission.
CONTACT: Investor Contact Information:
Danielle Spangler
The Trout Group
synergy@troutgroup.com
(646) 378-2924
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024